Expression of FAS/APO 1/CD 95 in thyroid tumors.

Marta Rzeszutko; Wojciech Rzeszutko; Piotr Dziegiel; Waldemar Balcerzak; Krzysztof Kaliszewski; Marek Bolanowski

Vol 45, No 2 (2007)

Original paper

Submitted: 2011-12-19

Published online: 2007-06-29

View PDF

Download PDF file

Get Citation

Expression of FAS/APO 1/CD 95 in thyroid tumors.

Marta Rzeszutko, Wojciech Rzeszutko, Piotr Dziegiel, Waldemar Balcerzak, Krzysztof Kaliszewski, Marek Bolanowski

Folia Histochem Cytobiol 2007;45(2):87-91.

Vol 45, No 2 (2007)

ORIGINAL PAPERS

Submitted: 2011-12-19

Published online: 2007-06-29

Abstract

Using immunohistochemistry, Fas/Apo-1 protein expression was investigated in thyroid cancers of 67 patients. Thyroid biopsies from twenty eight patients with benign thyroid diseases were also examined. The patients with thyroid cancer manifested a variable histology of the cancer, including 14 patients with follicular carcinoma, 48 with papillary carcinoma, 5 patients with medullary carcinoma. The benign thyroid disease involved nodular goitre in 11 patients and follicular adenoma in other 17 patients. The study aimed at examining immunohistochemical expression of Fas protein in order to determine whether the level of its expression correlated with histological diagnosis. In individual patients Fas expression was more prevalent in thyroid carcinomas as compared to benign tumors (p=0.001). A marked increase in Fas expression was found in papillary carcinoma, as compared to follicular and medullary carcinomas (p=0.02). In conclusion, Fas was significantly more frequently overexpressed in thyroid cancer, indicating its role in thyroid tumorigenesis.